<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893412</url>
  </required_header>
  <id_info>
    <org_study_id>2008/191</org_study_id>
    <nct_id>NCT00893412</nct_id>
  </id_info>
  <brief_title>Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography</brief_title>
  <official_title>Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography : a Randomized, Controlled, Double Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the analgetic effects of the fast-release orodispersible tramadol
      tablet.

      Tramadol acts through a weak affinity for μ receptors and secondly by inhibiting
      noradrenaline and serotonin neuronal reuptake. It has been used since the 1970s by over 50
      million people for the treatment of acute and chronic pain. The orodispersible Tramadol
      tablet is a new galenic form and is available on the Belgian market for the last three years.
      Pregastric absorption leads to a quicker onset of action.

      So far, evidence shows that pain during and immediately after the Hysterosalpingography (HSG)
      procedure is only significantly reduced by IV opioid analgesia. This study evaluates the
      analgetic potential of an orodispersible opioid tablet. This tablet disintegrates rapidly (in
      around 20-30 seconds) and may be taken without water. Its abuse potential is very low and its
      respiratory depressant effect is negligible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four arm prospective randomized double blinded trial

      Patients that need a HSG as part of their diagnostic work-up and are eligible for
      randomization are counseled about possible participation. After signing the informed consent
      patients will be randomized in one of the following four groups:

      Group 1: Fast-release Orodispersible Tramadol Tablet + metal cannula Group 2: Placebo + metal
      cannula Group 3: Fast-release Orodispersible Tramadol Tablet + balloon catheter Group 4:
      Placebo + balloon catheter

      Tablets are administered 30 min before the procedure

      Primary Endpoint:

        -  VAS at the six different assessment points

      Secondary Endpoint

        -  adverse effects and complications such as: nausea, vomiting, constipation, drowsiness,
           respiratory depression, hypotension, allergic reaction and infection
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS at the six different assessment points</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects and complications</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Infertility</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Tramadol + Metal cannula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fast-release Orodispersible Tramadol Tablet + Metal cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Metal cannula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Metal cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol + Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fast-release Orodispersible Tramadol Tablet + balloon catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Balloon</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + balloon catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)</intervention_name>
    <description>1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)</description>
    <arm_group_label>Tramadol + Metal cannula</arm_group_label>
    <arm_group_label>Tramadol + Balloon</arm_group_label>
    <other_name>Tradonal odis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hysterosalpingography (HSG)</intervention_name>
    <description>One HSG using a metal canula or balloon catheter, 30 minutes after tablet</description>
    <arm_group_label>Tramadol + Metal cannula</arm_group_label>
    <arm_group_label>Placebo + Metal cannula</arm_group_label>
    <arm_group_label>Tramadol + Balloon</arm_group_label>
    <arm_group_label>Placebo + Balloon</arm_group_label>
    <other_name>HSG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Metal cannula</arm_group_label>
    <arm_group_label>Placebo + Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 and &lt; 45 years

          -  Written informed consent

        Exclusion Criteria:

          -  Contra-indication to tramadol, morphine or to other opioids

               -  Concomitant use of MAO inhibitors or use less than 2 weeks prior to procedure

               -  Use of any other CNS-acting drug

          -  Contra-indication to radio-contrast medium (allergy)

          -  Patient already taking analgetics

          -  History of cervical stenosis

          -  Presence of pelvic inflammatory disease or any other condition causing pelvic pain

          -  Clinical and/or laboratory evidence of any major disease

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Devroey, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>May 4, 2009</last_update_submitted>
  <last_update_submitted_qc>May 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Paul Devroey</name_title>
    <organization>UZ Brussel</organization>
  </responsible_party>
  <keyword>HSG</keyword>
  <keyword>analgesia</keyword>
  <keyword>tramadol</keyword>
  <keyword>metal cannula</keyword>
  <keyword>balloon catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

